Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients

被引：49
作者：
Hermann, M [1 ]
Åsberg, A
Christensen, H
Holdaas, H
Hartmann, A
Reubsaet, JLE
机构：
[1] Univ Oslo, Sch Pharm, Dept Pharmacol, Oslo, Norway
[2] Natl Hosp, Dept Med, Lab Renal Physiol, Oslo, Norway
[3] Univ Oslo, Sch Pharm, Dept Pharmaceut Anal, Oslo, Norway
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 76卷 / 04期
关键词：
D O I：
10.1016/j.clpt.2004.07.008
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：388 / 391
页数：4
相关论文
共 50 条
[41]   EFFECT OF FELODIPINE ON RENAL HEMODYNAMICS AND TUBULAR SODIUM HANDLING IN CYCLOSPORINE-TREATED RENAL-TRANSPLANT RECIPIENTS [J].
SORENSEN, SS ;
SKOVBON, H ;
EISKJAER, H ;
THOMSEN, K ;
PEDERSEN, EB .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1992, 7 (01) :69-78
[42]   SYSTEMIC BUT NOT RENAL PRODUCTION OF PROSTACYCLIN IS HIGHLY REDUCED IN CYCLOSPORINE-TREATED HEART-TRANSPLANT RECIPIENTS [J].
BORDET, JC ;
DELORGERIL, M ;
DURBIN, S ;
BOISSONNAT, P ;
RENAUD, S ;
DUREAU, G ;
DECHAVANNE, M .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 72 (05) :486-487
[43]   Predictors of renal function improvement following tacrolimus conversion in cyclosporine-treated kidney transplant recipients [J].
Chang, H. R. ;
Lin, C. C. ;
Lian, J. D. .
TRANSPLANTATION PROCEEDINGS, 2007, 39 (10) :3135-3141
[44]   CLINICAL AND IMMUNOLOGICAL FEATURES OF CYTOMEGALOVIRUS-INFECTION IN CYCLOSPORINE-TREATED RENAL-TRANSPLANT RECIPIENTS [J].
BRANDO, B ;
CIVATI, G ;
BUSNACH, G ;
BROGGI, ML ;
BELLI, LS ;
SEVESO, M ;
BRUNATI, C ;
MINETTI, L .
TRANSPLANTATION PROCEEDINGS, 1985, 17 (06) :2683-2685
[45]   IMMUNOPHARMACODYNAMIC EVALUATION OF CYCLOSPORINE-TREATED RENAL-ALLOGRAFT RECIPIENTS [J].
ROGERS, AJ ;
YOSHIMURA, N ;
KERMAN, RH ;
KAHAN, BD .
TRANSPLANTATION, 1984, 38 (06) :657-664
[46]   COMPLETE REPLACEMENT OF METHYLPREDNISOLONE BY AZATHIOPRINE IN CYCLOSPORINE-TREATED PRIMARY CADAVERIC RENAL-TRANSPLANT RECIPIENTS [J].
KUPIN, W ;
VENKAT, KK ;
OH, HK ;
DIENST, S .
TRANSPLANTATION, 1988, 45 (01) :53-55
[47]   T-SUPPRESSOR CELL-FUNCTION IN CYCLOSPORINE-TREATED RENAL-TRANSPLANT RECIPIENTS [J].
BRANDO, B ;
CIVATI, G ;
BUSNACH, G ;
GRILLO, C ;
MINETTI, L .
TRANSPLANTATION PROCEEDINGS, 1984, 16 (06) :1639-1641
[48]   CORTICOSTEROID WITHDRAWAL WITH SUBSTITUTION OF AZATHIOPRINE IN CYCLOSPORINE-TREATED PRIMARY CADAVERIC RENAL-TRANSPLANT RECIPIENTS [J].
KUPIN, W ;
VENKAT, KK ;
FLORENCEGREEN, D ;
NORRIS, C ;
OH, HK ;
DIENST, S ;
LEVIN, NW .
TRANSPLANTATION PROCEEDINGS, 1987, 19 (01) :2024-2026
[49]   RENAL VASCONSTRICTION IN CYCLOSPORINE-TREATED (CY) TRANSPLANT RECIPIENTS (TXR) WITHOUT OTHER EVIDENCE OF NEPHROTOXICITY [J].
CURTIS, JJ ;
LUKE, RG ;
JONES, P ;
DUBOVSKY, EV ;
WHELCHEL, JD ;
DIETHELM, AG .
KIDNEY INTERNATIONAL, 1986, 29 (01) :428-428
[50]   Endothelin-1 plasma levels in cyclosporine-treated stable renal transplant patients [J].
Costa, C ;
Cauduro, RL ;
Lhulier, F ;
Cabral, RD ;
Garcia, RG ;
Manfro, RC .
TRANSPLANTATION PROCEEDINGS, 2002, 34 (02) :487-488
12345